Want to see IN:TARSONS full AI Analyst Report?
Top Page
Tarsons Products Limited
(TARSONS)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹335.00
▲(7.18% Upside)
Action:Reiterated
Date:09/22/26
The score is held back primarily by weakening profitability, rising debt, and persistently negative free cash flow, alongside a very high P/E valuation. Technicals are moderately supportive with price above major moving averages, but mixed momentum (negative MACD) limits the uplift.
Positive Factors
Recurring consumables demand
Tarsons sells repeat-purchase consumables such as pipette tips, tubes, and storage products used in routine laboratory workflows. This replenishment-led model can support recurring demand, while a broader portfolio may increase customer basket size and deepen product relevance.
Negative Factors
Profitability deterioration
Tarsons has experienced a material decline in earnings power and operating profitability compared with 2021–2023. Lower profit generated from a larger revenue base suggests weaker margins or efficiency, which could limit reinvestment and reduce resilience if recovery remains moderate.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables demand
Tarsons sells repeat-purchase consumables such as pipette tips, tubes, and storage products used in routine laboratory workflows. This replenishment-led model can support recurring demand, while a broader portfolio may increase customer basket size and deepen product relevance.
Read all positive factors
Tarsons Products Limited (TARSONS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹17.68B
Dividend Yield0.42%
Average Volume (3M)13.73K
Price to Earnings (P/E)163.5
Beta (1Y)1.01
Revenue Growth10.63%
EPS Growth-59.63%
CountryIN
Employees1,108
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)2.09
Shares Outstanding53,206,280
10 Day Avg. Volume11,378
30 Day Avg. Volume13,732
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)1.51
Price to Sales (P/S)2.27
P/FCF Ratio-134.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.7
Revenue Forecast (FY)₹4.88B
Tarsons Products Limited Business Overview & Revenue Model
Company Description
Established in 1983 and headquartered in Kolkata, India, Tarsons Products Limited specializes in the global manufacturing and distribution of plastic laboratory supplies and scientific instruments. The company's diverse product portfolio features ...
How the Company Makes Money
Tarsons makes money primarily by manufacturing and selling laboratory consumables (largely plastic, single-use and repeat-purchase items) to customers such as research labs, diagnostic labs, hospitals, academic institutions, and life-science/bioph...
Tarsons Products Limited Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
55
Neutral
Cash Flow
42
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.41B | 4.23B | 3.92B | 2.96B | 2.83B | 3.01B |
| Gross Profit | 1.11B | 1.12B | 1.35B | 985.42M | 1.25B | 1.49B |
| EBITDA | 1.32B | 1.18B | 1.27B | 1.11B | 1.42B | 1.61B |
| Net Income | 110.95M | 143.22M | 297.70M | 426.40M | 807.14M | 1.01B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 11.86B | 10.80B | 9.72B | 7.26B | 5.44B |
| Cash, Cash Equivalents and Short-Term Investments | 252.56M | 252.56M | 256.52M | 226.11M | 590.58M | 774.42M |
| Total Debt | 0.00 | 3.93B | 3.39B | 2.69B | 1.11B | 216.65M |
| Total Liabilities | -6.35B | 5.51B | 4.50B | 3.59B | 1.56B | 543.96M |
| Stockholders Equity | 6.35B | 6.35B | 6.30B | 6.13B | 5.69B | 4.90B |
Cash Flow | ||||||
| Free Cash Flow | -267.75M | -71.03M | -550.87M | -816.28M | -1.14B | -485.02M |
| Operating Cash Flow | 444.51M | 1.18B | 966.20M | 1.03B | 755.99M | 834.67M |
| Investing Cash Flow | -783.05M | -1.30B | -1.47B | -2.85B | -1.79B | -1.38B |
| Financing Cash Flow | 321.34M | 89.33M | 578.12M | 1.36B | 845.61M | 1.30B |
Tarsons Products Limited Technical Analysis
Positive
312.55
Price Trends
328.21
Positive
290.73
Positive
248.78
Positive
Market Momentum
2.75
Negative
57.31
Neutral
62.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TARSONS, the sentiment is Positive. The current price of 312.55 is below the 20-day moving average (MA) of 325.12, below the 50-day MA of 328.21, and above the 200-day MA of 248.78, indicating a bullish trend. The MACD of 2.75 indicates Negative momentum. The RSI at 57.31 is Neutral, neither overbought nor oversold. The STOCH value of 62.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:TARSONS.
Tarsons Products Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | ₹25.85B | 31.76 | ― | 0.35% | 14.22% | 7.17% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₹165.45B | 51.95 | ― | 0.22% | 18.31% | -12.86% | |
52 Neutral | ₹21.66B | 72.05 | ― | 0.15% | 195.95% | 1526.86% | |
50 Neutral | ₹7.43B | 178.79 | ― | 0.15% | 7.55% | -57.19% | |
47 Neutral | ₹17.68B | 163.49 | ― | 0.42% | 10.63% | -59.63% | |
45 Neutral | ₹1.27B | -9.13 | ― | ― | -29.72% | 47.98% |
* General Sector Average
IN:TARSONS
Tarsons Products Limited
342.00
47.20
16.01%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
59.96
-15.97
-21.03%
IN:POLYMED
Poly Medicure Limited
1,615.05
-293.04
-15.36%
IN:VIMTALABS
Vimta Labs Limited
568.05
-174.56
-23.51%
IN:ZIMLAB
Zim Laboratories Ltd.
146.50
76.01
107.83%
IN:FISCHER
Fischer Medical Ventures Ltd
32.64
-64.51
-66.40%
Tarsons Products Limited Corporate Events
Tarsons Clarifies Share Volume Surge, Affirms Full Regulatory Compliance
Sep 21, 2026
Tarsons Products Limited, an ISO-certified manufacturer in the laboratory and life-sciences consumables space, is headquartered in Kolkata and listed on the National Stock Exchange of India under the symbol TARSONS. The company serves institutiona...
Tarsons Products Publishes Q1 FY27 Investor Presentation for Market Disclosure
Aug 10, 2026
Tarsons Products Limited has released an investor presentation detailing its financial results for the quarter ended June 30, 2026, and submitted the same to both the BSE and NSE in line with SEBI disclosure regulations. The document, prepared und...
Tarsons Posts Q1 FY27 Results and Sets Date for 43rd AGM
Aug 10, 2026
Tarsons Products Limited reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, as approved by its board of directors in a meeting held on August 10, 2026. The results, accompanied by a limited re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.